IOVA News and Press, Iovance Biotherapeutics Inc. From 05/26/23

Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- Iovance Biot...

2023-05-09 22:26:03 ET Iovance Biotherapeutics, Inc. (IOVA) Q1 2023 Earnings Conference Call May 09, 2023 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Communications Fred Vogt – Interim Presid...

2023-05-09 16:05:36 ET Iovance Biotherapeutics press release ( NASDAQ: IOVA ): Q1 GAAP EPS of -$0.50 beats by $0.26 . For further details see: Iovance Biotherapeutics GAAP EPS of -$0.50 beats by $0.26

First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a lat...

2023-05-08 17:35:56 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.73 Over the last 1 year, IOVA has beaten EPS estimates 50% of the time and has be...

SAN CARLOS, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2023 financial results on Tuesday, May 9, 2023. Management will host a conferen...

2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-04-24 18:41:25 ET Summary Acceptance of the BLA of Iovance Biotherapeutics' Lifileucel for review by the FDA is expected in the coming months; the first step towards potentially receiving U.S. marketing approval of this therapy. Upon BLA acceptance of Lifileucel, the FDA will...

2023-04-23 05:10:46 ET Summary Iovance Biotherapeutics has made progress in developing potency assays for lifileucel, a tumor-infiltrating lymphocyte therapy for advanced melanoma patients. Developing potency assays for lifileucel is complex for cell-based therapies, but Iovance w...

2023-04-20 09:45:00 ET After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. Still, scores of beaten-down tech and biotech stocks remain woefully undervalued right now. As a result, there is a s...